



GAU 1617
Jfw

P/1259-636

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Date: July 27, 2004

Fernand LABRIE

Confirmation No.: 4181

Serial No.: 10/052,824

Group Art Unit: 1617

Filed: November 7, 2001

Examiner: S. Jiang

For: SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION
WITH ESTROGENS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Submitted herewith is a copy of art together with a form listing the same for the convenience of the Examiner.

I respectfully request that the information submitted be considered and enclose our Check No. 17601 in payment of the required \$180.00 fee.

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee due during the pendency of this application is not paid, the Patent and Trademark Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450, on July 27, 2004

Respectfully submitted,

Name of applicant, assignee or
Registered Representative

Signature

July 27, 2004

Date of Signature

William O. Gray, III

Registration No.: 30,944

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700

WOG:db
Enclosures

00665713.1

08/02/2004 MBIZUNES 00000020 10052824

01 FC:1806

180.00 OP



APPLICATION'S ART CITATION (Attach several sheets if necessary)								Application 10/052,824		OFGS File No. P/1259-636		
								Applicant Fernand LABRIE				
								Filing Date November 7, 2001		Group Art Unit 1617		
U.S. PATENT DOCUMENTS												
Examiner Initial	Document Number							Date	Name	Class	Sub- class	Filing Date If Appropriate
	Document Number							Date	Country	Class	Sub- class	Translation
												Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
1.	K. Abrahamsson et al., "Transient reduction of human left ventricular mass in carnitine depletion induced by antibiotics containing pivalic acid," Br. Heart J. 74:656-659, 1995.											
2.	K. Abrahamsson et al., "Pivalic acid-induced carnitine deficiency and physical exercise in humans," Metabolism 45(12):1501-1507, 1996.											
3.	K. Abrahamsson et al., "Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration - a risk irrespective of age, biochemical and molecular medicine," 55(1):77-79, 1995.											
4.	I. Ito et al., "Alteration of ammonia and carnitine levels in short-term treatment with pivalic acid-containing prodrug," Tohoku J. of Exp. Med. 175(1):43-53, 1995.											
5.	K. Abrahamsson et al., "Impaired ketogenesis in carnitine depletion caused by short-term administration of pivalic acid prodrug," Biochem. Med. and Met. Biol. 52(1):18-21, 1994.											
6.	Y. Toyonaga et al., "Effect of cefditoren povoxil on carnitine metabolism in pediatric patients," Japan Journal of Antibiotics 46(10):926-937, 1993.											
7.	M. Tanimura et al., "Carnitine status and safety after administration of S-1108, a new oral cephem, to patients," Antimicrobial Agents and Chemotherapy 37(5):1043-1049, 1993.											
8.	Couillard, S.; Labrie, C.; Gauthier, S.; Labrie, F., Abstract, <i>Maturitas</i> , (1997), Vol. 27, No. SUPPL., pp. 80, Title: "Inhibitory Effect of a new Non-Steroidal Pure Antiestrogen (EM-800) in Combination with DHEA on Human ZR-75-1 Breast Tumors in Nude Mice".											
Examiner								Date Considered				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.												